A randomized, double-blind, cross-over, 4-period, 4 treatment, with-subject placebo-controlled study to assess the optimal renoprotective dose of aliskiren in hypertensive type 2 diabetic patients with incipient or overt nephropathy

Trial Profile

A randomized, double-blind, cross-over, 4-period, 4 treatment, with-subject placebo-controlled study to assess the optimal renoprotective dose of aliskiren in hypertensive type 2 diabetic patients with incipient or overt nephropathy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Diabetic nephropathies; Hypertension; Proteinuria
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 03 Feb 2011 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 01 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
    • 22 Jun 2008 The expected completion date for this trial has been extended from May 2008 to July 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top